Clinical Trial Update: Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed glioblastoma was terminated, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• HSPPC-96 (heat shock protein peptide complex-96)
• Pembrolizumab (Keytruda) (pembrolizumab)
• Temozolomide (Temodar) (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2024-02-28